| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | VP30 |
| Uniprot No | Q77DJ5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-288aa |
| 氨基酸序列 | MEASYERGRPRAARQHSRDGHDHHVRARSSSRENYRGEYRQSRSASQVRVPTVFHKKRVEPLTVPPAPKDICPTLKKGFLCDSSFCKKDHQLESLTDRELLLLIARKTCGSVEQQLNITAPKDSRLANPTADDFQQEEGPKITLLTLIKTAEHWARQDIRTIEDSKLRALLTLCAVMTRKFSKSQLSLLCETHLRREGLGQDQAEPVLEVYQRLHSDKGGSFEAALWQQWDRQSLIMFITAFLNIALQLPCESSAVVVSGLRTLVPQSDNEEASTNPGTCSWSDEGTP |
| 预测分子量 | 38.0kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于VP30重组蛋白的示例性参考文献(内容为模拟概括，实际引用请核实原始文献)：
---
1. **文献名称**：*Functional analysis of Ebola virus VP30 recombinant protein in viral transcription*
**作者**：Mühlberger E. et al.
**摘要**：研究通过重组表达埃博拉病毒VP30蛋白，发现其磷酸化状态调控病毒RNA聚合酶活性，并证实VP30是病毒基因组转录的必要辅助因子。
---
2. **文献名称**：*Structural characterization of recombinant VP30 from Marburg virus and its role in nucleocapsid assembly*
**作者**：Modrof J. et al.
**摘要**：利用大肠杆菌系统重组表达马尔堡病毒VP30蛋白，解析其晶体结构，揭示其通过结合病毒核衣壳蛋白NP调控病毒颗粒组装的分子机制。
---
3. **文献名称**：*Development of a VP30-dependent Ebola virus minigenome system for antiviral screening*
**作者**：Watanabe S. et al.
**摘要**：构建依赖重组VP30蛋白的埃博拉病毒微型基因组模型，验证其在抗病毒药物高通量筛选中的应用潜力，强调VP30作为治疗靶点的价值。
---
(注：以上为学术示例，具体文献需通过PubMed/Google Scholar等平台以关键词“VP30 recombinant protein”或“Ebola VP30 function”检索核实。)
VP30 recombinant protein is a key component in the study of Ebola virus (EBOV) biology and therapeutic development. VP30. encoded by the EBOV genome, is a multifunctional phosphoprotein that plays a critical role in viral transcription and replication. As part of the nucleocapsid complex, it interacts with other viral proteins, including NP, VP35. and the RNA-dependent RNA polymerase L, to regulate the switch between viral mRNA synthesis and genome replication. Unlike most non-segmented negative-strand RNA viruses, EBOV relies on VP30 to initiate transcription, making it a unique target for antiviral strategies.
Recombinant VP30 is typically produced using heterologous expression systems, such as *E. coli* or mammalian cell cultures, followed by purification via affinity chromatography. Its recombinant form retains structural and functional properties comparable to the native protein, enabling researchers to study its interactions with viral RNA, host factors, and potential inhibitors. Structural analyses reveal that VP30 contains a C-terminal zinc-binding domain essential for oligomerization and RNA binding, while N-terminal regions mediate interactions with NP and VP35.
The protein's phosphorylation status, modulated by host kinases, influences its transcriptional activity, providing insights into viral replication mechanisms. Recombinant VP30 serves as a vital tool for *in vitro* assays, structural studies, and high-throughput screening of antiviral compounds targeting EBOV. It has also been explored as a component of diagnostic kits and vaccine candidates. Current research focuses on disrupting VP30's functions through small-molecule inhibitors or monoclonal antibodies, offering potential avenues for therapeutic intervention against Ebola virus disease.
×
